Search clinical trials for: Adjuvants, Immunologic

Total 39406 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Epimmune

Unknown

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Kenya...

Completed

A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants

Malaria,Falciparum

Kenya
University of Maryland, Baltimore
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Prostate Cancer
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center

Completed

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Ovarian Cancer | Peritoneal Cancer | Fallopian Tubes

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
TVAX Biomedical

Completed

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

Glioma | Glioblastoma Multiforme | High Grade Astrocytoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage II Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage I Pancreatic Cancer | Stage II Non-small Cell Lung Cancer | Stage III Colon Cancer and other conditions

United States
QLT Inc.

Completed

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma (Mel48)

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin) | Non-melanomatous Skin Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
MabVax Therapeutics, Inc.

Completed

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

United States
Tang-Du Hospital

Recruiting

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Carcinoma, Non-Small-Cell Lung | Neoplasm, Residual | Circulating Tumor DNA | Next-Generation Sequencing | Chemotherapy, Adjuvant

China
Cliniques universitaires Saint-Luc- Université...
Immutep S.A.S.

Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Melanoma

Belgium
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Breast Cancer

United States
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Curevo Inc
Green Cross Corporation; Mogam Biotechnology Research Institute

Active, not recruiting

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Herpes Zoster | Shingles

United States
Centre Hospitalier Universitaire Vaudois

Completed

Immunotherapy of Melanoma Patients

Melanoma

Switzerland
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Nonneoplastic Condition

United States
TVAX Biomedical

Completed

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

Glioblastoma Multiforme | Grade IV Astrocytoma | Grade IV Glioma

United States
The University of Texas Medical Branch, Galveston
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
National Institute of Allergy and Infectious Diseases...

Recruiting

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Chronic HIV Infection

United States
TVAX Biomedical

Available

TVI-Brain-1 in Expanded Access Patient

Recurrent Glioblastoma

United States
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Jiangsu Province Centers for Disease Control and...
Bejing Vigoo Biological Co., LTD

Completed

A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children

EV71-associated Disease

China
Novartis Vaccines

Completed

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

Influenza

Korea, Republic of
Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Innovive Pharmaceuticals

Completed

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Myelodysplastic Syndromes | Leukemia | Lung Cancer | Malignant Mesothelioma | Primary Peritoneal Cavity Cancer

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
GlaxoSmithKline

Unknown

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Tel-Aviv Sourasky Medical Center

Unknown

Vaccination Against Influenza H1N1 in Rheumatic Diseases

Rheumatic Diseases | Influenza
National Cancer Institute, Naples

Recruiting

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

Hepatocellular Carcinoma

Italy
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Breast Cancer

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Immune Response BioPharma, Inc.

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Multiple Sclerosis

United States
National Cancer Institute (NCI)

Completed

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States

Search clinical trials for: Adjuvants, Immunologic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations